STALEY CAPITAL ADVISERS’s Phathom Pharmaceuticals PHAT Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,000	Closed	-$95.9K	–	201
2025 Q2	$95.9K	Hold	10,000	–	–	﹤0.01%	188
2025 Q1	$62.7K	Hold	10,000	–	–	﹤0.01%	187
2024 Q4	$81.2K	Hold	10,000	–	–	﹤0.01%	176
2024 Q3	$181K	Hold	10,000	–	–	0.01%	176
2024 Q2	$103K	Hold	10,000	–	–	﹤0.01%	176
2024 Q1	$106K	Hold	10,000	–	–	0.01%	180
2023 Q4	$91.3K	Hold	10,000	–	–	﹤0.01%	174
2023 Q3	$104K	Hold	10,000	–	–	0.01%	168
2023 Q2	$143K	Hold	10,000	–	–	0.01%	175
2023 Q1	$71K	Hold	10,000	–	–	﹤0.01%	175
2022 Q4	$112K	Hold	10,000	–	–	0.01%	163
2022 Q3	$111K	Buy	+10,000	New	+$95.3K	0.01%	164

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

STALEY CAPITAL ADVISERS's PHAT Position: Q3 2025 in Review

STALEY CAPITAL ADVISERS sold out of Phathom Pharmaceuticals (PHAT) in Q3 2025, closing a stake of 10,000 shares — an estimated $95.9K sold.

STALEY CAPITAL ADVISERS first reported a position in PHAT in Q3 2022 and held it in 12 quarters. The position peaked at $181K in Q3 2024. 133 funds tracked by Wall St. Rank hold PHAT as of Q3 2025.

STALEY CAPITAL ADVISERS reported no remaining Phathom Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
STALEY CAPITAL ADVISERS sold 10,000 Phathom Pharmaceuticals shares in Q3 2025, an estimated $95.9K.
STALEY CAPITAL ADVISERS first reported a position in Phathom Pharmaceuticals in Q3 2022 and held it in 12 quarters.
STALEY CAPITAL ADVISERS's Phathom Pharmaceuticals position peaked at $181K in Q3 2024.
133 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2025.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q3 2025, filed 12 Nov 2025.